193 related articles for article (PubMed ID: 28977607)
1. Skeletal and Uterotrophic Effects of Endoxifen in Female Rats.
Gingery A; Iwaniec UT; Subramaniam M; Turner RT; Pitel KS; McGovern RM; Reid JM; Marler RJ; Ingle JN; Goetz MP; Hawse JR
Endocrinology; 2017 Oct; 158(10):3354-3368. PubMed ID: 28977607
[TBL] [Abstract][Full Text] [Related]
2. Comparative uterotrophic effects of endoxifen and tamoxifen in ovariectomized Sprague-Dawley rats.
Schweikart KM; Eldridge SR; Safgren SL; Parman T; Reid JM; Ames MM; Goetz MP; Davis MA
Toxicol Pathol; 2014 Dec; 42(8):1188-96. PubMed ID: 24670817
[TBL] [Abstract][Full Text] [Related]
3. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside.
Jayaraman S; Reid JM; Hawse JR; Goetz MP
Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34480554
[TBL] [Abstract][Full Text] [Related]
4. The effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeleton.
Gingery A; Subramaniam M; Pitel KS; Reese JM; Cicek M; Lindenmaier LB; Ingle JN; Goetz MP; Turner RT; Iwaniec UT; Spelsberg TC; Hawse JR
PLoS One; 2014; 9(5):e98219. PubMed ID: 24853369
[TBL] [Abstract][Full Text] [Related]
5. Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats.
Nuttall ME; Bradbeer JN; Stroup GB; Nadeau DP; Hoffman SJ; Zhao H; Rehm S; Gowen M
Endocrinology; 1998 Dec; 139(12):5224-34. PubMed ID: 9832463
[TBL] [Abstract][Full Text] [Related]
6. Effects of the selective estrogen receptor modulator ospemifene on bone in rats.
Kangas L; Härkönen P; Väänänen K; Peng Z
Horm Metab Res; 2014 Jan; 46(1):27-35. PubMed ID: 24108389
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen.
Wu X; Subramaniam M; Grygo SB; Sun Z; Negron V; Lingle WL; Goetz MP; Ingle JN; Spelsberg TC; Hawse JR
Breast Cancer Res; 2011 Mar; 13(2):R27. PubMed ID: 21392396
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the pharmacologic profile of a standardized soy extract in the ovariectomized rat model of menopause: effects on bone, uterus, and lipid profile.
Gallo D; Zannoni GF; Apollonio P; Martinelli E; Ferlini C; Passetti G; Riva A; Morazzoni P; Bombardelli E; Scambia G
Menopause; 2005; 12(5):589-600. PubMed ID: 16145313
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent effects of 4-hydroxytamoxifen, the active metabolite of tamoxifen, on estrogen receptor-alpha expression in the rat uterus.
Reed CA; Berndtson AK; Nephew KP
Anticancer Drugs; 2005 Jun; 16(5):559-67. PubMed ID: 15846122
[TBL] [Abstract][Full Text] [Related]
10. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
Wu X; Hawse JR; Subramaniam M; Goetz MP; Ingle JN; Spelsberg TC
Cancer Res; 2009 Mar; 69(5):1722-7. PubMed ID: 19244106
[TBL] [Abstract][Full Text] [Related]
11. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
Qu Q; Zheng H; Dahllund J; Laine A; Cockcroft N; Peng Z; Koskinen M; Hemminki K; Kangas L; Väänänen K; Härkönen P
Endocrinology; 2000 Feb; 141(2):809-20. PubMed ID: 10650964
[TBL] [Abstract][Full Text] [Related]
12. Effects of two novel selective estrogen receptor modulators, raloxifene, tamoxifen, and ethinyl estradiol on the uterus, vagina and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis).
Sikoski P; Register TC; Lees CJ; Lundeen S; Hutchison J; Brown KH; Cline JM
Am J Obstet Gynecol; 2007 Jan; 196(1):75.e1-7. PubMed ID: 17240242
[TBL] [Abstract][Full Text] [Related]
13. Comparison of estrogenic responses in bone and uterus depending on the parity status in Lewis rats.
Keiler AM; Bernhardt R; Scharnweber D; Jarry H; Vollmer G; Zierau O
J Steroid Biochem Mol Biol; 2013 Jan; 133():101-9. PubMed ID: 23032373
[TBL] [Abstract][Full Text] [Related]
14. Ovarian status influences the skeletal effects of tamoxifen in adult rats.
Sibonga JD; Evans GL; Hauck ER; Bell NH; Turner RT
Breast Cancer Res Treat; 1996; 41(1):71-9. PubMed ID: 8932878
[TBL] [Abstract][Full Text] [Related]
15. Evidences for antiosteoporotic and selective estrogen receptor modulator activity of silymarin compared with ethinylestradiol in ovariectomized rats.
El-Shitany NA; Hegazy S; El-Desoky K
Phytomedicine; 2010 Feb; 17(2):116-25. PubMed ID: 19577454
[TBL] [Abstract][Full Text] [Related]
16. Strain differences in tamoxifen sensitivity of Sprague-Dawley and Fischer 344 rats.
Bailey JA; Nephew KP
Anticancer Drugs; 2002 Oct; 13(9):939-47. PubMed ID: 12394257
[TBL] [Abstract][Full Text] [Related]
17. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.
Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD
Menopause; 2006; 13(4):609-20. PubMed ID: 16837883
[TBL] [Abstract][Full Text] [Related]
18. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S
Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
[TBL] [Abstract][Full Text] [Related]
19. Effects of tamoxifen and ethynylestradiol cotreatment on uterine gene expression in immature, ovariectomized mice.
Fong CJ; Burgoon LD; Williams KJ; Jones AD; Forgacs AL; Zacharewski TR
J Mol Endocrinol; 2010 Sep; 45(3):161-73. PubMed ID: 20628019
[TBL] [Abstract][Full Text] [Related]
20. The effects of the selective estrogen receptor modulators, methyl-piperidino-pyrazole (MPP), and raloxifene in normal and cancerous endometrial cell lines and in the murine uterus.
Davis AM; Ellersieck MR; Grimm KM; Rosenfeld CS
Mol Reprod Dev; 2006 Aug; 73(8):1034-44. PubMed ID: 16688783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
